State Street SPDR S&P Pharmaceuticals ETF
XPH
65 hedge funds and large institutions have $117M invested in State Street SPDR S&P Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 9 closing their positions.
3.44% more ownership
Funds ownership: 75.34% → 78.78% (+3.4%)
7% less funds holding
Funds holding: 70 → 65 (-5)
9% less capital invested
Capital invested by funds: $129M → $117M (-$11.9M)
30% less call options, than puts
Call options by funds: $783K | Put options by funds: $1.12M
36% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 25
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
+$1.92M |
| 2 |
Envestnet Portfolio Solutions
Chicago,
Illinois
|
+$1.91M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.13M |
| 4 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$325K |
| 5 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.58M |
| 2 |
Rockefeller Capital Management
New York
|
-$1.49M |
| 3 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$950K |
| 4 |
CI
CX Institutional
Auburn,
Indiana
|
-$739K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$730K |
XPH Hedge Fund Activity: Q2 2025 in Review
65 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2025, worth a combined $117M — down 9.3% from $129M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of XPH and 5 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 16 added.
The largest buyer was First Citizens Bank & Trust, adding an estimated $1.92M. The largest seller was Bank of America, cutting an estimated $1.58M.
- 65 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2025, down from 70 in Q1 2025.
- Funds reported $117M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2025, down 9.3% quarter-over-quarter.
- 5 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2025 and 9 closed out, a net change of -4 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2025 was First Citizens Bank & Trust, an estimated $1.92M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2025 was Bank of America, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2025.